Emergent BioSolutions Completes BioThrax Study

Emergent BioSolutions has completed a human study that will be used to support expanding the indication for BioThrax to include post-exposure prophylaxis (PEP) for individuals exposed to anthrax.

This trial focused on the immunogenicity of a three-dose BioThrax regimen when used for PEP in adults. The primary objective was to determine the timing and peak of the immune response following three doses of BioThrax, Emergent said.

The company has submitted a final report for this trial to HHS, which triggers a $8.8 million payment under the terms of the $448 million contract.